The possibility of obtaining marketing authorization of orphan pharmaceutical compounding preparations: 3,4-DAP for Lambert-Eaton Myasthenic Syndrome

Author(s):
Wilde, S. de; Jong, M.G.H. de; Lipka, A.F.; Guchelaar, H.J. (0000-0002-7085-1383); Schimmel, K.J.M.
Published
2018
Publication type
Article / Letter to editor
Decision makingHospital medicinesPharmaceutical compounding preparationsOrphan drugsLEMS3,4-DAP
Date issued
2018-03-01
Language
English
Is part of
European Journal of Pharmaceutical Sciences (2018), Vol. 114, p. 24-29
hdl
1887/95572
doi
10.1016/j.ejps.2017.11.025